UBS Group Reiterates Buy Rating for Craneware (LON:CRW)

Craneware (LON:CRW)‘s stock had its “buy” rating reaffirmed by equities researchers at UBS Group in a research note issued to investors on Wednesday, MarketBeat.com reports. They currently have a GBX 570 price target on the stock. UBS Group’s target price would indicate a potential downside of 57.48% from the company’s current price.

Other analysts have also recently issued reports about the company. Berenberg Bank reiterated a “buy” rating and set a GBX 2,900 price target on shares of Craneware in a research report on Tuesday, January 20th. Shore Capital Group reaffirmed a “buy” rating and set a GBX 2,850 target price on shares of Craneware in a research note on Tuesday, January 20th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Craneware presently has an average rating of “Buy” and a consensus target price of GBX 2,297.75.

Craneware Price Performance

LON:CRW opened at GBX 1,340.50 on Wednesday. Craneware has a 12 month low of GBX 1,290 and a 12 month high of GBX 2,644. The stock has a 50 day moving average of GBX 1,535.95 and a two-hundred day moving average of GBX 1,936.90. The company has a current ratio of 0.76, a quick ratio of 1.00 and a debt-to-equity ratio of 7.93. The firm has a market cap of £476.00 million, a P/E ratio of 24.28 and a beta of 0.28.

Craneware Company Profile

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operational transformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus® cloud ecosystem unifies data, revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance, improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster – that simplify the complexities of healthcare finance and operations.